https://vitasmlab.net

VIRPNEMARK

Viral Pneumonia Targeted Library

Viral pneumonia is a major global health threat, causing severe respiratory illness, high hospitalization rates, and significant mortality, particularly among vulnerable populations like the elderly, immunocompromised individuals, and children. Patho- gens such as influenza, RSV, and SARS-CoV-2 are highly contagious, leading to rapid spread during outbreaks and pandemics. This strains healthcare systems and results in substantial economic losses. Current treatments are often limited in efficacy, and antiviral resistance is a growing concern. Finding new drugs targeting viral pneumonia is critical to address these challenges. Novel therapeutics can improve outcomes by offering more effective, broad-spectrum, and resistance-proof options. They are also essential for combating emerging and re-emerging viruses, ensuring preparedness for future outbreaks. Investing in drug discovery for viral pneumonia not only saves lives but also reduces healthcare burdens and enhances global pandemic resilience, making it a pressing public health priority.



Example Targets:

H5N1 H1N1 Respiratory syncytial virus (RSV)

Herpes simplex virus Varicella-zoster virus



STL041822



STK476547



STK013484

Viral Pneumonia Targeted Library (VIRPNEMARK) consists of compounds with potential antiviral activity, which were select- ed based on similarity to known effectors of proteins, associated with pneumonia. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. It is designed in a way that maximizes structural diversity and excludes problematic compounds. This library has 4885 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at

irina@vitasmlab.biz

Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!

Empowering Your Research, One Molecule at a Time.